Retinoids as chemopreventive and therapeutic agents

Drugs of the Future

Volumn 23, Issue 6, 1998, Pages 621-634

  Sun, Shi Yong ^a   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; 5 AZA 2' DEOXYCYTIDINE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ALPHA INTERFERON; BEXAROTENE; BUTYRIC ACID; CD 2314; COLECALCIFEROL; DACTINOMYCIN; DIMETHYL SULFOXIDE; DNA; ETRETIN; ETRETINATE; HEXAMETHYLENEBISACETAMIDE; INTERFERON; N (4 CARBOXYPHENYL)RETINAMIDE; N,N DIMETHYLFORMAMIDE; ONCOPROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RECEPTOR; RETINOIC ACID; RETINOID; RETINOL PALMITATE; RO 41 5253; TAMOXIFEN; TAZAROTENE; TIAZOFURIN; TIOGUANINE; TRANSFORMING GROWTH FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ACTINIC KERATOSIS; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DNA SYNTHESIS; DYSPLASTIC NEVUS; ERYTHROPLASIA; HEADACHE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; LEUKOPLAKIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PSORIASIS; REVIEW; TERATOGENICITY; TOPICAL DRUG ADMINISTRATION; UTERINE CERVIX DYSPLASIA;

EID: 0031848363     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.06.858360     Document Type: Review

References (135)

1. Sporn, M., Dunlop, N., Newton, D., Smith, J. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35: 1332-8.
2. Lotan, R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem Biophys Acta 1980, 605: 33-91.
3. Gudas, L.J., Sporn, M.B., Roberts, A.B. Cellular biology and biochemistry of the retinoids. In: The Retinoids. Sporn, M.B., Roberts, A.B., Goodman, D.S. (Eds.). Raven Press: New York 1994, 443-520.
4. DeLuca, L.M. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J 1991, 5: 2924-33.
5. Lotan, R. Retinoids and apoptosis: Implication for cancer chemoprevention and therapy. J Natl Cancer Inst 1995, 87: 1655-7.
6. Lippman, S.M., Kessler, J., Meyskens, F. Retinoids as preventive and therapeutic anticancer agents (part 1). Cancer Treat Rep 1987, 71: 391-405.
7. Rosen, J., Day, A., Jones, T.K., Jones, E.T.T., Nadzan, A.M., Stein, R.B. Intracellular receptors and signal transducers and activators of transcription superfamilies: Novel targets for small-molecule drug discovery. Med Chem 1995, 38: 4855-74.
8. Steinberg, J. In cancer, retinoic acid brings hope, but no more miracles. J NIH Res 1996, 8: 28-9.
9. Delescluse, C., Cavey, M.T., Martin, B. et al. Selective high affinity retinoic acid receptor beta-gamma ligands. Mol Pharmacol 1991, 40: 556-62.
10. Lehmann, J.M., Dawson, M.I., Hobbs, P.D., Husmann, M., Pfahl, M. Identification of retinoids with nuclear receptor subtype-selective activities. Cancer Res 1991, 51: 4804-9.
11. Lehmann, J.M., Jong, L., Fanjul, A. et al. Retinoids selective for retinoid X receptor response pathways. Science 1992, 258: 1944-6.
12. Bernard, B.A., Bernardon, J-M., Delescluse, C. et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ. Biochem Biophys Res Commun 1992, 186: 977-83.
13. Boehm, M.F., Zhang, L., Badea, B.A. et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994, 37: 2930-41.
14. Fanjul, A., Dawson, M.I., Hobbs, P.D. et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994, 372: 107-10.
15. Dawson, M.I., Jong, L., Hobbs, P.D. et al. Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity. J Med Chem 1995, 38: 3368-83.
16. Charpentier, B., Bernardon, J-M., Eustache, J. et al. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J Med Chem 1995, 38: 4993-5006.
17. Eyrolies, L., Kagechika, H., Kawachi, E. et al. Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring. J Med Chem 1994, 37: 1508-17.
18. Johnson, A.T., Klein, E.S., Gillett, S.J. et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem 1996, 38: 4764-7.
19. Johnson, A.T., Klein, E.S., Wang, L., Pino, M.E., Chandrartna, R.A.S. Identification of a retinoic acid receptor beta subtype specific agonist. J Med Chem 1997, 39: 5027-30.
20. Warrell, R. Frankel, S., Miller, W. et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl J Med 1991, 324: 1385-93.
21. Chen, Z-X., Xue, Y-Q., Zang, R. et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patient. Blood 1991, 78: 1413-9.
22. Hong, W.K., Endicott, J., Iri, L.M. et al. 13-cis-Retinoic acid in the treatment of oral leukoplasia. New Engl J Med 1986, 315: 1501-5.
23. Hong, W.K., Lippman, S.M., Itri, L.M. et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. New Engl J Med 1990, 323: 795-801.
24. 2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992, 84: 235-41.
25. 2a. Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992, 84: 241-5.
26. 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1993, 85: 499-500.
27. Kelloff, G.J., Boone, C.W., Crowell, J.A. et al. New agents for cancer chemoprevention. J Cell Biochem 1996, 26S: 1-28.
28. Esgleyes-Ribot, T., Chandraratna, R.A.S., Lew-Kaya, D., Sefton, J., Duvic, M.J. Response of psoriasis to a new topical retinoid, AGN190168. J Am Acad Dermatol 1994, 30: 581-90.
29. Rizvi, N.A., Marshall, J.L., Loewen, G.R. et al. A phase I study of Targretin, an RXR-selective retinoid agonist. Proc Am Cancer Res 1996, 37: 165.
30. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995, 11: 493-504.
31. Oridate, N., Higuchi, M., Suzuki, S., Shroot, B., Hong, W. K., Lotan, R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437). Int J Cancer 1997, 70: 484-7.
32. Schadendorf, D., Kern, M.A., Artuc, M. et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol 1996, 135: 1889-98.
33. Sun, S-Y., Yue, P., Shroot, B., Hong, W.K., Lotan, R. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. J Cell Physiol 1997, 173: 279-84.
34. Apfel, C., Bauer, F., Creftaz, M. et al. Retinoic acid receptor alpha antagonist selectivity counteracts retinoic acid effects. Proc Natl Acad Sci USA 1992, 89: 7129-33.
35. Wieder, J.M., Lowe, N.J. Systemic retinoids for psoriasis. Dermatol Clin 1995, 13: 891-6.
36. Tutoryan, T., Gilchrest, B.A. Retinoids and the skin. Nutr Res 1994, 52: 299-310.
37. Biro, D.E., Shalita, A.R. Clinical aspects of topical retinoids. Skin Pharmacol 1993, 6(Suppl. 1): 53-60.
38. Hong, W.K., Itri, L.M. Retinoids and human cancer. In: The Retinoids. Sporn, M.B., Roberts, A.B., Goodman, D.S. (Eds.). Raven Press: New York 1994, 597-658.
39. Hong, W.K., Lippman, S.M., Hittelman, W.N., Lotan, R. Retinoid chemoprevention of aerodigestive cancer from basic research to the clinic. Clin Cancer Res 1995, 1: 677-861.
40. Lippman, S.M., Benner, S.E., Hong, W.K. The chemoprevention of cancer. In: Cancer Prevention and Control. Greenwald, P., Kramer, R.S., Weed, D.L. (Eds.). Marcel Dekker: New York 1995, 329-52.
41. Moon, R.C., Mehta, R.G., Rao, K.J.V.N. Retinoids and cancer in experimental animals. In: The Retinoids. Sporn, M.B., Roberts, A.B., Goodman, D.S. (Eds.). Raven Press: New York 1994, 573-95.
42. Lotan, R. Retinoids in chemoprevention. FASEB J 1996, 10: 1031-9.
43. Hennings, H., Wenk, M.L.M., Donahoe, R. Retinoic acid promotion of papilloma formation in mouse skin. Cancer Lett 1982, 16: 1-5.
44. Verma, A.K., Conrad, E.A., Boutwell, R.K. Differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the complete carcinogenesis process and by the initiation-promotion regimen. Cancer Res 1982, 42: 3519-25.
45. Fischer, S.M., Klein-Szanto, A.J.P., Adamas, L.M. et al. The first stage and complete promoting activity of retinoic acid but not the analog Ro-10-9359. Carcinogenesis 1985, 6: 575-8.
46. Bavinck, J.N., Tieben, L.M., Van der Woude, F.J. et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study. J Clin Oncol 1995, 13: 1933-8.
47. Rook, A.H., Jaworsky, C., Nguyen, T. et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995, 59: 714-9.
48. Edwards, L., Jaffe, P. The effects of topical tretinoin on dysplastic nevi. Arch Dermatol 1990, 126: 494-9.
49. Halpern, A.C., Schuchter, L.M., Elder, D.E. et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 1994, 12: 1028-35.
50. Omenn, G.S., Goodman, G.E., Thomquist, M.D. et al. Risk factors for lung cancer and for intervention effects in CARET, the β-carotene and retinol efficacy trial. J Natl Cancer Inst 1996, 88: 1550-9.
51. Albanes, D., Heinonen, O.P., Taylor, P.R. et al. α-Tocopherol and β-carotene supplements and lung cancer incidence in the α-tocopherol, β-carotene cancer prevention study: Effects of baseline characteristics and study compliance. J Natl Cancer Inst 1996, 88: 1560-70.
52. Beenken, S.W., Huang, P., Sellers, M. et al. Retinoid modulation of biomarkers in oral leukoplakia/dysplasia. J Cell Biochem 1994, 19(Suppl.): 270-7.
53. Chiesa, F., Tradati, N., Marazza, M. et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem 1993, 17(Suppl.): 255-61.
54. Costa, A., Formelli, F., Chiesa, F. et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994, 54(Suppl.): 2032s-7s.
55. Lee, J.S., Lippman, S.M., Benner, S.E. et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994, 12: 937-45.
56. Meyskens, F.L., Surwit, E., Moon, T.E. et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 1994, 86: 539-43.
57. Han, J. Highlights of the cancer chemoprevention studies in China. Prev Med 1993, 22: 712-22.
58. Peck, G.L., DiGiovanna, J.J. Synthetic retinoids in dermatology. In: The Retinoids. Sporn, M.B., Roberts, A.B., Goodman, D.S. (Eds.). Raven Press: New York 1994, 631-58.
59. Bolla, M., Lefur, R., Ton Van, J. et al. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 1994, 30A: 767-72.
60. Pastorino, U., Infante, M., Maioli, M. et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993, 11: 1216-22.
61. De Palo, G., Veronesi, U., Camerini, T. et al. Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 1995, 87: 146-7.
62. Prout, G.R. Jr., Barton, B.A. 13-cis-Retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem 1992, 161(Suppl.): 148-52.
63. Studer, U.E., Jenzer, S., Biedermann, C. et al. Adjuvant treatment with vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors - Final analysis of a prospective randomized multicenter trial in Switzerland. Eur Urol 1995, 28: 284-90.
64. Amos, B., Lotan, R. Retinoid sensitive cells and cell lines. In: Methods in Enzymology: Retinoids. Packer, L. (Ed.). Academic Press: Orlando 1991, 190: 217-25.
65. Lotan, R., Lotan, D., Sacks, P. Inhibition of tumor cell growth by retinoids. In: Methods in Enzymology: Retinoids. Packer, L. (Ed.). Academic Press: Orlando 1991, 190: 100-10.
66. Meyskens, F.L. Jr., Salmon, S.E. Inhibition of human melanoma colony formation by retinoids. Cancer Res 1979, 39: 4055-7.
67. Meyskens, F.L. Jr., Alberts, D.S., Salmon, S.E. Effect of 13-cis-retinoic acid and 4-hydroxyphenyl-all-trans-retinamide on human tumor colony formation in soft agar. Int J Cancer 1983, 32: 295-9.
68. Cowan, J.D., Von Hoff, D.D., Dinesman, A., Clark, G. Use of a human tumor cloning system to screen retinoids for antineoplastic activity. Cancer 1983, 51: 92-6.
69. Placentini, M., Annicchiarico-Petruzzelli, M., Olivedo, S. et al. Phenotype-specific "tissue" transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: Correlation with cell death by apoptosis. Int J Cancer 1992, 52: 271-8.
70. Gottardis, M.M., Lamph, W.W., Shalinsky, D.R., Wellstein, A., Heyman, R.A. The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res Treat 1996, 38: 85-96.
71. Martin, S.J., Bradley, J.G., Cotter, T.G. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990, 79: 448-53.
72. Delia, D., Aiello, A., Lombardi, L. et al. N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993, 53: 6036-41.
73. Delia, D., Aiello, A., Fornelli, F. et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl)retinamide and effect of deregulated bcl-2. Blood 1995, 85: 359-67.
74. Madfti, A., Marcora, E., Bunone, G. et al. N-(4-hydroxyphenyl)retinamide, a potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 1994, 86: 1245-7.
75. Di Vinci, A., Geido, E., Infusini, E., Giaretti, W. Neuroblastoma cells apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide. Int J Cancer 1994, 59: 422-6.
76. Ponzoni, M., Bocca, P., Chiesta, V. et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation. Cancer Res 1995, 55: 853-61.
77. Kalemkerian, G.P., Slusher, R., Ramalingam, S., Gadgeel, S., Mabry, M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 1995, 87: 1674-80.
78. Oridate, N., Lotan, D., Xu, X-C., Hong, W.K., Lotan, R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous carcinoma cell lines. Clin Cancer Res 1996, 2: 855-63.
79. Oridate, N., Lotan, D., Mitchell, M.F., Hong, W.K., Lotan, R. Induction of apoptosis by retinoids in human cervical carcinoma cell lines. Int J Oncol 1995, 7: 433-41.
80. Sheikh, M.S., Shao, Z-M., Li, X-S. et al. N-(4-Hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995, 16: 2477-86.
81. Wang, T.T., Phang, J.M. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 1996, 107: 65-71.
82. Hsieh, T.C., Ng, C., Wu, J.M. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem Mol Biol Int 1995, 37: 499-506.
83. Roberson, K.M., Penland, S.N. Padilla, G.M. et al. Fenretinide: Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth Differ 1997, 8: 101-11.
84. Atencia, R., Garcia-Sanz, M., Unda, F., Arechaga, J. Apoptosis during retinoic acid-induced differentiation of F9 embryonal carcinoma cells. Exp Cell Res 1994, 214: 663-7.
85. Anzai, N., Kawabata, H., Hirama, T. et al. Marked apoptosis of human myelomonocytic leukemia cell line P39: Significance of cellular differentiation. Leukemia 1994, 8: 446-53.
86. Nagy, L., Thomazy, V.A., Chandraratna, R.A., Heyman, R.A., Davies, P.J. Retinoid-regulated expression of Bcl-2 and tissue transglutaminase during the differentiation and apoptosis of human myeloid leukemia (HL-60) cells. Leukemia Res 1996, 20: 499-505.
87. Nagy, L., Thomazy, V.A., Shipley, G.L. et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995, 15: 3540-51.
88. Bissonnette, R.P., Brunner, T., Lazarchik, S.B. et al. 9-cis-Retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation. Mol Cell Biol 1995, 15: 5576-85.
89. Seewaldt, V.L., Johnson, B.S., Parker, M.B., Collins, S.J., Swisshelm, K. Expression of retinoic acid receptor β mediates retinoic acid-induced growth inhibition and apoptosis in breast cancer cells. Cell Growth Differ 1995, 6: 1077-88.
90. Liu, Y., Lee, M.O., Wang, H.G. et al. Retinoic acid receptor β mediates the growth-inhibitory effects of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 1996, 16: 1138-49.
91. Horn, V., Minucci, S., Ogryzko, V.V. et al. RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal carcinoma cells. FASEB J 1996, 10: 1071-7.
92. Clifford, J., Chiba, H., Sobieszczuk, D., Metzger, D., Chambon, P. RXRα-null F9 embryonal carcinoma cells are resistant to the differentiation, anti-proliferative and apoptotic effects of retinoids. EMBO J 1996, 15: 4142-55.
93. Agarwal, N., Mehta, K. Possible involvement of bcl-2 pathway in retinoin X receptor α-induced apoptosis of HL-60 cells. Biochem Biophys Res Commun 1997, 230: 251-3.
94. Mehta, K., McQueen, T., Neamati, N., Collins, S., Andreeff, M. Activation of retinoid receptor RAR α and RXR α induce differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 1997, 7: 179-86.
95. Fanjul, A.N., Delia, D., Pierotti, M.A., Rideout, D., Qiu, J., Pfahl, M. 4-Hydroxyphenylretinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996, 271: 22441-6.
96. Supino, R., Crosti, M., Clerici, M. et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996, 65: 491-7.
97. Delia, D., Aiello, A., Meroni, L. et al. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997, 18: 943-8.
98. Oridate, N., Suzuki, S., Higuchi, M. et al. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997, 89: 1191-8.
99. Sun, S-Y., Yue, P., Hong, W.K., Lotan, R. Differential growth inhibitory effects of RAR-/RXR-selective retinoids in human head and neck cancer cells. Proc Am Assoc Cancer Res 1997, 38: 174.
100. Lotan, R. Retinoids and squamous cell differentiation. In: Retinoids in Oncology. Hong, W.K., Lotan, R. (Eds). Marcel Dekker: New York 1993, 43-72.
101. Strickland, S., Smith, K.K., Marotti, K.R. Hormonal induction of differentiation in teratocarcinoma stem cells: Generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell 1980, 21: 347-55.
102. Andrews, P.W. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol 1984, 103: 285-93.
103. McBurney, M.W., Jones-Villeneuve, E.M., Edwards, M.K., Anderson, P.J. Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line. Nature 1982, 299: 165-7.
104. Breitman, T.R., Selonick, S.E., Collins, S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL60) by retinoic acid. Proc Natl Acad Sci USA 1980, 77: 2936-40.
105. Damjanov, I., Horvat, B., Gibas, Z. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest 1993, 68: 220-32.
106. Boncinelli, E., Simeone, A., Acampora, D., Mavilio, F. HOX gene activation by retinoic acid. Trends Genet 1991, 7: 329-34.
107. Luscher, B., Mitchell, P.J., Williams, T., Tjian, R. Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Gene Dev 1989, 3: 1507-17.
108. Breitman, T.R., He, R.Y. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990, 50: 6268-73.
109. Fontana, J.A. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol 1987, 55: 136-44.
110. Grant, S., Bhalia, K., Weinstein, I.B., Pestka, S., Mileno, M.D., Fisher, P.B. Recombinant human interferon sensitizes resistant myeloid leukemic cells to induction of terminal differentiation. Biochem Biophys Res Commun 1985, 130: 379-88.
111. Bollag, W., Peck, R., Frey, J.R. Inhibition of proliferation by retinoids and cytokines and their combination in four human transformed epithelial cell lines. Cancer Lett 1992, 62: 167-72.
112. 3 and analogs. J Cell Biochem 1994, 56: 427-35.
113. Higuchi, T., Hannigan, G.E., Malkin, D., Yeger, H., Williams, B.R. Enhancement by retinoic acid and dibutyryl cyclic adenosine 3′:5′-monophosphate of the differentiation and gene expression of human neuroblastoma cells induced by interferon. Cancer Res 1991, 51: 3958-64.
114. Widschwendter, M., Daxenbichler, G., Gulig, Z. et al. Activity of retinoic acid receptor-gamma selective binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. Int J Cancer 1997, 71: 497-504.
115. Kolla, V., Weihua, X., Kalvakolanu, D.V. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997, 272: 9742-8.
116. Shalinsky, D.R., Bischoff, E.D., Gregory, M.L. et al. Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice. Cancer Res 1995, 55: 3183-91.
117. Mourad, W.A., Bruner, J.M., Vallieres, E. et al. The effect of high dose vitamin A on the morphology and proliferative activity of xenograft lung and head and neck cancer. In Vivo 1996, 10: 329-33.
118. Abemayor, E., Chang, B., Sidell, N. Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett 1990, 55: 1-5.
119. Comaglia-Ferraris, P., Mariottini, G.L., Ponzoni, M. γ-Interferon and retinoic acid synergize in inhibiting the growth of human neuroblastoma cells in nude mice. Cancer Lett 1992, 61: 215-20.
120. Dahiya, R., Zhang, D.Y., Ho, R.J. et al. Regression of LNCaP human prostate tumor xenografts in athymic nude mice by 13-cis-retinoic acid and androgen ablation. Biochem Mol Biol Int 1995, 35: 487-98.
121. Pienta, K.J., Nguyen, N.M., Lehr, J.E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993, 53: 224-6.
122. Liu, D.F., Rabbani, S.A. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Prostate 1995, 27: 269-79.
123. Halter, S.A., Fraker, L.D., Adcock, D., Vick, S. Effect of retinoids on xenotransplanted human mammary carcinoma cells in athymic mice. Cancer Res 1988, 48: 3733-6.
124. Rosewicz, S., Stier, U., Brembeck, F. et al. Retinoids: Effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cells. Gastroenterology 1995, 109: 1646-60.
125. Bold, R.J., Ishizuka, J., Townsend, C.M. Jr., Thompson, J.C. All-trans-retinoic acid inhibits growth of human pancreatic cancer cell lines. Pancreas 1996, 12: 189-95.
126. Jiang, S.Y., Shyu, R.Y., Chen, H.Y. et al. In vitro and in vivo growth inhibition of SC-M1 gastric cancer cells by retinoic acid. Oncology 1996, 53: 334-40.
127. Formelli, F., Cleris, L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993, 53: 5374-6.
128. Schleicher, R.L., Moon, R.C., Patel, M.K., Beattie, C.W. Influence of retinoids on growth and metastasis of hamster melanoma in athymic mice. Cancer Res 1988, 48: 1465-9.
129. Shalinsky, D.R., Bischoff, E.D., Lamph, W.W. et al. A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res 1997, 57: 162-8.
130. Lu, X-P., Fanjul, A., Picard, N. et al. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med 1997, 3: 686-90.
131. Huang, M.E., Ye, Y.C., Chair, J.R. et al. All-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72: 567-72.
132. Degos, L., Chomienne, C., Deniel, M.T. et al. Treatment of first relapse in acute promyelocytic leukemia with all-trans-retinoic acid. Lancet 1990, 336: 1440-1.
133. de The, H., Degos, L., Warrell, R.P. Jr. Clinical and molecular advances in acute promyelocytic leukemia. In: Retinoids in Oncology. Gegos, L., Parkinson, D.R. (Eds.). Springer-Verlag: New York 1995, 73-88.
134. Parkinson, D.R., Warrell, R.P. Jr. Retinoid therapy of other haematological malignancies. In: Retinoids in Oncology. Degos, L., Parkinson, D.R. (Eds.). Springer-Verlag: New York 1995, 89-92.
135. Pastorino, U., Parkinson, D.R., Chiesa, F. Retinoids in the prevention and therapy of solid tumors. In: Retinoids in Oncology. Degos, L., Parkinson, D.R. (Eds.). Springer-Verlag: New York 1995, 93-111.